StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR - Free Report) in a report released on Monday. The brokerage issued a sell rating on the stock.

A number of other research firms also recently commented on NSPR. Piper Sandler reiterated an "overweight" rating and issued a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital initiated coverage on InspireMD in a report on Wednesday, December 11th. They set a "buy" rating and a $5.00 target price on the stock.

InspireMD Stock Performance

NYSE:NSPR opened at $2.76 on Monday. The stock has a market cap of $71.99 million, a price-to-earnings ratio of -3.68 and a beta of 0.99. InspireMD has a one year low of $1.81 and a one year high of $3.42. The business's 50-day simple moving average is $2.77 and its 200 day simple moving average is $2.71.

InspireMD (NYSE:NSPR - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.81 million during the quarter, compared to analysts' expectations of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period in the prior year, the business posted ($0.15) EPS. On average, equities research analysts predict that InspireMD will post -0.79 EPS for the current year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 104,081 shares of the company's stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned approximately 0.42% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.